Ari Illeperuma

1.6k total citations · 2 hit papers
13 papers, 1.2k citations indexed

About

Ari Illeperuma is a scholar working on Epidemiology, Pharmacology and Hepatology. According to data from OpenAlex, Ari Illeperuma has authored 13 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Epidemiology, 4 papers in Pharmacology and 4 papers in Hepatology. Recurrent topics in Ari Illeperuma's work include Hepatitis C virus research (3 papers), Treatment of Major Depression (3 papers) and Substance Abuse Treatment and Outcomes (3 papers). Ari Illeperuma is often cited by papers focused on Hepatitis C virus research (3 papers), Treatment of Major Depression (3 papers) and Substance Abuse Treatment and Outcomes (3 papers). Ari Illeperuma collaborates with scholars based in United States, Sri Lanka and United Kingdom. Ari Illeperuma's co-authors include Bernard L. Silverman, David R. Gastfriend, Walter Ling, Edward V. Nunes, Evgeny Krupitsky, Stefan Zeuzem, Rafael Esteban, Hendrik W. Reesink, Christophe Hézode and Evguenia S. Svarovskaia and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Ari Illeperuma

13 papers receiving 1.1k citations

Hit Papers

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3 2011 2026 2016 2021 2014 2011 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
    2014 592 citations Stefan Zeuzem, Geoffrey Dusheiko et al. New England Journal of Medicine profile →
  2. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial
    2011 400 citations Evgeny Krupitsky, Edward V. Nunes et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ari Illeperuma United States 7 857 588 353 133 132 13 1.2k
Paolo Mezzelani Italy 18 506 0.6× 334 0.6× 123 0.3× 64 0.5× 27 0.2× 49 907
Arantza Sanvisens Spain 17 455 0.5× 234 0.4× 80 0.2× 129 1.0× 34 0.3× 61 745
R. Solà Spain 16 262 0.3× 232 0.4× 136 0.4× 62 0.5× 108 0.8× 69 897
Daniel Fuster Spain 19 658 0.8× 451 0.8× 55 0.2× 199 1.5× 32 0.2× 66 1.0k
Edith Collins Australia 17 251 0.3× 113 0.2× 252 0.7× 44 0.3× 346 2.6× 22 1.2k
Gregory Whelan Australia 14 570 0.7× 125 0.2× 41 0.1× 24 0.2× 94 0.7× 28 1.2k
Kunling Wu United States 17 274 0.3× 67 0.1× 89 0.3× 797 6.0× 86 0.7× 39 1.6k
Janis Durelle United States 14 505 0.6× 154 0.3× 69 0.2× 295 2.2× 51 0.4× 16 989
Leen Naji Canada 14 230 0.3× 21 0.0× 292 0.8× 21 0.2× 89 0.7× 31 721
Dominic Labriola United States 12 469 0.5× 96 0.2× 66 0.2× 765 5.8× 19 0.1× 29 1.4k

Countries citing papers authored by Ari Illeperuma

Since Specialization
Citations

This map shows the geographic impact of Ari Illeperuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ari Illeperuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ari Illeperuma more than expected).

Fields of papers citing papers by Ari Illeperuma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ari Illeperuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ari Illeperuma. The network helps show where Ari Illeperuma may publish in the future.

Co-authorship network of co-authors of Ari Illeperuma

This figure shows the co-authorship network connecting the top 25 collaborators of Ari Illeperuma. A scholar is included among the top collaborators of Ari Illeperuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ari Illeperuma. Ari Illeperuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Zeuzem, Stefan, Geoffrey Dusheiko, Riina Salupere, et al.. (2014). Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. New England Journal of Medicine. 370(21). 1993–2001. 592 indexed citations breakdown →
2.
Zeuzem, Stefan, Marta Colombo, Robert Flisiak, et al.. (2014). P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL. Journal of Hepatology. 60(1). S452–S452. 5 indexed citations
3.
Zeuzem, Stefan, Robert Flisiak, Ari Illeperuma, et al.. (2014). Su1064 Early Viral Kinetics Do Not Predict Treatment Outcome With Sofosbuvir + Ribavirin for 12 or 24 Weeks in HCV Genotype 2/3 Patients in the Valence Trial. Gastroenterology. 146(5). S–978. 1 indexed citations
4.
Illeperuma, Ari, et al.. (2012). Prevalence of histology proven Helicobacter pylori infection in a cohort of Sri Lankan patients with gastric carcinoma. Ceylon Medical Journal. 57(2). 86–86. 1 indexed citations
5.
Nunes, Edward V., Walter Ling, Ari Illeperuma, et al.. (2012). [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].. PubMed. 112(5 Pt 2). 3–11. 6 indexed citations
6.
Krupitsky, Evgeny, Edward V. Nunes, Walter Ling, et al.. (2011). Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. The Lancet. 377(9776). 1506–1513. 400 indexed citations breakdown →
7.
Krupitsky, Evgeny, Ari Illeperuma, David R. Gastfriend, & Bernard L. Silverman. (2011). P.6.c.001 Efficacy and safety of extended-release injectable naltrexone for the treatment of opioid dependence. European Neuropsychopharmacology. 21. S576–S576. 1 indexed citations
8.
Krupitsky, Evgeny, Edward V. Nunes, Walter Ling, et al.. (2011). Injectable extended-release naltrexone for opioid dependence. The Lancet. 378(9792). 665–665. 23 indexed citations
9.
Illeperuma, Ari, et al.. (2010). Is routine histological examination of gall bladder specimens justifiable?. Ceylon Medical Journal. 55(1). 13–13. 17 indexed citations
10.
Lapham, Sandra C., Robert Forman, Mark E. Alexander, Ari Illeperuma, & Michael J. Bohn. (2008). The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients. Journal of Substance Abuse Treatment. 36(1). 1–6. 19 indexed citations
11.
Lucey, Michael R., Bernard L. Silverman, Ari Illeperuma, & Charles P. O’Brien. (2008). Hepatic Safety of Once‐Monthly Injectable Extended‐Release Naltrexone Administered to Actively Drinking Alcoholics. Alcoholism Clinical and Experimental Research. 32(3). 498–504. 36 indexed citations
12.
Dunbar, Joi, Ari Illeperuma, Jasmina Milovanović, et al.. (2004). A placebo- and active comparator-controlled dose escalation study of the pharmacokinetics, pharmacodynamics, and safety of inhaled large porous particle (AIR®) epinephrine in normal volunteers. Journal of Allergy and Clinical Immunology. 113(2). S260–S260. 6 indexed citations
13.
Cook, David M., Beverly M. K. Biller, M. L. Vance, et al.. (2002). The Pharmacokinetic and Pharmacodynamic Characteristics of a Long-Acting Growth Hormone (GH) Preparation (Nutropin Depot) in GH-Deficient Adults. The Journal of Clinical Endocrinology & Metabolism. 87(10). 4508–4514. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo Mezzelani Breakdown of academic impact, for papers by Arantza Sanvisens Breakdown of academic impact, for papers by R. Solà Breakdown of academic impact, for papers by Daniel Fuster Breakdown of academic impact, for papers by Edith Collins Breakdown of academic impact, for papers by Gregory Whelan Breakdown of academic impact, for papers by Kunling Wu Breakdown of academic impact, for papers by Janis Durelle Breakdown of academic impact, for papers by Leen Naji Breakdown of academic impact, for papers by Dominic Labriola
Rankless by CCL
2026